IP Library Granted Patent US 7,790,762
Granted Patent B2
US 7,790,762 · App. 11/280,959 · Granted Sep 7, 2010

Compounds and methods for thiol-containing compound efflux and cancer treatment

Assignee: National Jewish Health
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,762
App. No.
11/280,959
Granted
Sep 7, 2010
Kind
B2
Abstract

Methods for therapy of cystic fibrosis and other conditions such as cancer are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing compounds within the cell. Therapeutic methods involve the administration of such agents to a patient afflicted with cystic fibrosis, cancer and/or another condition responsive to stimulation of thiol-containing compound transport.

Claims (13)

1. A compound of the formula:

wherein R 1 is a positively charged imidazole ring wherein the two nitrogens are substituted with C 1-4 alkyl substituents; and

each of R2′, R3′, R5′ and R6′ is independently hydrogen or a hydroxyl protecting group and wherein at least one of R2′, R3′, R5′, or R6′ is —OH.

2. The compound of claim 1 , wherein R2′ or R3′ is —OH.

3. The compound of claim 1 , wherein R2′ and R6′ or R2′ and R5′ or R2′ and R3′ are hydroxyl groups.

4. The compound of claim 3 , wherein R2′ and R6′ are hydroxyl groups.

5. The compound of claim 1 , wherein one of R2′, R3′, R5′ and R6′ is —OH and the others are hydrogen.

6. The compound of claim 1 , wherein R 1 is an imidazolium-2-yl, imidazolium-4-yl or imidazolium-5-yl.

7. The compound of claim 1 , wherein R 1 is an N—C 1-4 alkyl imidazolium-2-yl, N—C 1-4 alkyl imidazolium-4-yl or N—C 1-4 alkyl imidazolium-5-yl.

8. The compound of claim 1 , wherein the 5-membered heteroaryl ring is substituted imidazolium, R2′ is a hydrogen, R3′ is —OH, R5′ is a hydrogen, and R6′ is —OH.

9. A pharmaceutical composition comprising one or more compounds of claim 1 or pharmaceutically acceptable salts thereof.

10. The pharmaceutical composition of claim 9 , further comprising one or more of a pharmaceutically acceptable additive, carrier or excipient.

11. The pharmaceutical composition of claim 9 , further comprising an anti-cancer agent, a thiol-containing compound transporter inducing agent or a combination thereof.

Assignments (3)
CHANGE OF NAME Recorded Jun 30, 2010
From: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
To: NATIONAL JEWISH HEALTH
Reel/Frame 024620/0950 →
CONFIRMATORY LICENSE Recorded Jun 25, 2008
From: NATIONAL JEWISH CTR FOR IMMNLGY/RESP M
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021150/0091 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2006
From: DAY, BRIAN J.; KACHADOURIAN, REMY
To: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
Reel/Frame 017206/0253 →
Continuity (3)
Continuation In Part 1040098000 · Mar 27, 2003
Provisional Application 6042280200 · Oct 31, 2002
Related Publication 20060135585A1 · Jun 22, 2006